July 24, 2019 / 4:53 AM / 5 months ago

BRIEF-Lonza Expands Bioconjugation Facility

July 24 (Reuters) - Lonza Group AG:

* LONZA EXPANDS BIOCONJUGATION FACILITY AND ANNOUNCES APPROVAL OF THIRD COMMERCIAL ADC

* EXPANSION TO BIOCONJUGATION FACILITY IN VISP, SWITZERLAND TO MEET INCREASING CLINICAL, LAUNCH AND COMMERCIAL MARKET DEMAND

* FACILITY RECENTLY APPROVED FOR COMMERCIAL MANUFACTURE OF THIRD ANTIBODY-DRUG-CONJUGATE (ADC)

* ALL ADC ELEMENTS CURRENTLY AVAILABLE UNDER A SINGLE QUALITY SYSTEM IN LONZA NETWORK AND FROM 2020 AT A SINGLE SITE Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below